GB525 Unit 8 Regulatory Comparison Example

Canada or Australia for a Magnesium and Sleep Supplement Line: A Unit 8 Regulatory Comparison

[Student Name]

Purdue University Global

GB525: Global Business Environment

Unit 8 Regulatory Comparison

[Instructor Name]

[Date]

The supplement maker, its products and its plans are composite; the regulatory systems described and the sources cited are real, and readers should confirm current requirements with each regulator.

The Firm and Its Goal

Wasatch Daily Health sells two products in the United States: a magnesium glycinate capsule and a sleep formula combining magnesium, L-theanine and 3 mg of melatonin. Both sell online and through health food stores, and both are regulated in the United States as dietary supplements, which do not need approval before sale. The firm wants one export market within a year and has narrowed the choice to Canada and Australia, both English-speaking, both with strong online health retail and both reachable through distributors it already knows.

Tariffs are set aside early. For these products, import duties in either market are small relative to the cost of meeting each country's product rules. Ghemawat (2001) notes that the administrative distance created by different rules often outweighs the costs that firms first think of when entering a market.

Six Rules, Side by Side

1. Pre-market authorization. Canada regulates these products as natural health products. Each must hold a product license, shown by an eight-digit Natural Product Number on the label, before it can be sold (Health Canada, n.d.). Australia regulates them as complementary medicines. Low-risk products can be listed on the Australian Register of Therapeutic Goods, receiving an AUST L number, through a process in which the sponsor certifies that the product meets the requirements (Therapeutic Goods Administration, n.d.). Both systems require action before sale, unlike the US system the firm knows.

2. Claims allowed. In Canada, claims must be supported by evidence, and the fastest route to a license is to use a Health Canada monograph, a published standard listing approved ingredients, doses and claims. In Australia, listed medicines may only use indications chosen from a list of permitted indications, and the sponsor must hold evidence for each. Wasatch's US label claim that its sleep formula "supports restful sleep" is close to wording available in Canada's monographs; in Australia, the claim would need to match a permitted indication exactly.

3. Status of melatonin. This rule decides much of the comparison. In Canada, melatonin is permitted in natural health products, and a monograph covers its use for sleep. In Australia, melatonin is generally a prescription medicine, with only narrow exceptions for pharmacist supply of specific products. The sleep formula as it stands cannot be listed in Australia.

One ingredient decides half of the product line: the sleep formula can be licensed in Canada, but in Australia melatonin cannot be sold as a listed supplement at all.

4. Manufacturing standards. Canada requires a site license for manufacturers, packagers, labelers and importers of natural health products and requires good manufacturing practices. Australia requires that overseas manufacturers of listed medicines show compliance with good manufacturing practice, usually through a clearance process based on an acceptable inspection. Wasatch's contract manufacturer in Salt Lake City is inspected under US rules but has not been through either country's process.

5. Labeling. Canada requires labels in both English and French, with specific information including the product number, recommended use and risk information. Australia requires labels that meet its labeling order for non-prescription medicines, including the AUST L number and required statements. Both would require new labels; Canada's bilingual requirement adds design and translation cost.

6. Advertising. Australia's advertising code for therapeutic goods restricts how medicines may be promoted, and social media posts and influencer content can count as advertising. Canada requires that advertising be consistent with the product's license. The firm's US marketing, which relies on customer testimonials, would need review in both markets, and more extensive changes in Australia.

What the Comparison Shows

Canada's system is closer to what Wasatch needs: both products can be licensed, mostly through existing monographs, and the main costs are the product licenses, bilingual labels and an importer with a site license. Australia's system allows the magnesium capsule but not the sleep formula as it stands, and its rules on claims and advertising are stricter.

The time required also differs. Products that fit a Canadian monograph can often be licensed within a few months. For Australia, the listing itself can be quick, but the manufacturer's good manufacturing practice clearance and the evidence for each permitted indication can take longer.

Cost of Entry in Each Market

In composite estimates from the firm's regulatory consultant, Canadian entry would need about $48,000 of first-year spending: product license applications prepared by a consultant, bilingual label design and translation, an importer's fees and a first review of marketing copy. Australian entry with the magnesium capsule alone would cost about $62,000, most of it for the manufacturer's good manufacturing practice clearance and the evidence files behind each permitted indication. Reformulating the sleep product for Australia would add development and testing costs, roughly $35,000, before any sales.

The revenue side also favors Canada. Its larger population and the firm's existing relationships with two Canadian online retailers suggest first-year sales near $600,000 for both products, against about $250,000 for the magnesium capsule alone in Australia. On cost per dollar of expected first-year sales, Canada is roughly three times as attractive.

Recommendation

Enter Canada first, with both products. Apply for product licenses using Health Canada monographs, appoint a Canadian importer that holds a site license, and redesign labels in English and French. Adjust marketing so that every claim matches the licensed wording.

Consider Australia in the second year with the magnesium capsule and a reformulated sleep product without melatonin, such as magnesium with L-theanine and glycine, using indications from the permitted list. Begin the manufacturer's good manufacturing practice clearance now, since it is the step most likely to delay Australian entry.

Risks and Limits

Regulatory requirements change, and the descriptions here should be confirmed with each regulator and a local regulatory consultant before any filing. Product license decisions in Canada can take longer if a product does not fit a monograph. In Australia, the regulator checks a share of listed medicines after listing and can cancel listings that lack evidence, so the firm's evidence files must be complete before listing. Finally, the reformulated sleep product would be a new product with its own market test; its sales may not match the original's.

Conclusion

Tariffs barely separate Canada from Australia for this product line. The rules that bind before sale, what may be claimed and which ingredients are permitted, decide the choice. Canada accepts both products with manageable changes; Australia accepts one now and the other only after reformulation.

References

Ghemawat, P. (2001). Distance still matters: The hard reality of global expansion. Harvard Business Review, 79(8), 137-147.

Health Canada. (n.d.). Natural and non-prescription health products. Government of Canada.

Therapeutic Goods Administration. (n.d.). Listed complementary medicines. Australian Government Department of Health, Disability and Ageing.